Andrew F. Auld

Andrew F. Auld

Auto-generated profile, based on publicly available information

Andrew F. Auld

Centers for Disease Control and Prevention, Lilongwe, Malawi

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AAAndrew F. Auld
Andrew F. Auld
FMFrancisco Mbofana
Francisco Mbofana
RSRay W. Shiraishi
Ray W. Shiraishi
MSMauro Sanchez
Mauro Sanchez
CACharity Alfredo
Charity Alfredo
TETedd Ellerbrock
Tedd Ellerbrock
In Mozambique during 2004–2007 numbers of adult patients (≥15 years old) enrolled on antiretroviral therapy (ART) increased about 16-fold, from <5,000 to 79,500. All ART patients were eligible for co-trimoxazole. ART program outcomes, and determinants of outcomes, have not yet been reported. In a retrospective cohort study, we investigated rates of mortality, attrition (death, loss to follow-up, or treatment cessation), immunologic treatment failure, and regimen-switch, as well as determinants of selected outcomes, among a nationally representative sample of 2,596 adults initiating ART during 2004–2007. At ART initiation, median age of patients was 34 and 62% were female. Malnutrition and advanced disease were common; 18% of patients weighed <45 kilograms, and 15% were WHO stage IV. Median baseline CD4+ T-cell count was 153/µL and was lower for males than females (139/µL vs. 159/µL, p<0.01). Stavudine, lamivudine, and nevirapine or efavirenz were prescribed to 88% of patients; only 31% were prescribed co-trimoxazole. Mortality and attrition rates were 3.4 deaths and 19.8 attritions per 100 patient-years overall, and 12.9 deaths and 57.2 attritions per 100 patient-years in the first 90 days. Predictors of attrition included male sex [adjusted hazard ratio (AHR) 1.5; 95% confidence interval (CI), 1.3–1.8], weight 60 kg), WHO stage IV (AHR 1.7; 95% CI, 1.3–2.4, reference group WHO stage I/II), lack of co-trimoxazole prescription (AHR 1.4; 95% CI, 1.0–1.8), and later calendar year of ART initiation (AHR 1.5; 95% CI, 1.2–1.8). Rates of immunologic treatment failure and regimen-switch were 14.0 and 0.6 events per 100-patient years, respectively. ART initiation at earlier disease stages and scale-up of co-trimoxazole among ART patients could improve outcomes. Research to determine reasons for low regimen-switch rates and increasing rates of attrition during program expansion is needed.

28 November 2014
Verified
Journal Article
Closed access
AAAndrew F. Auld
Andrew F. Auld
SASimon G. Agolory
Simon G. Agolory
RSRay W. Shiraishi
Ray W. Shiraishi
FWFred Wabwire-Mangen
Fred Wabwire-Mangen
GKGideon Kwesigabo
Gideon Kwesigabo
TETedd V. Ellerbrock
Tedd V. Ellerbrock

17 September 2014 in Tropical Medicine & International Health
Verified
Journal Article
Open access
PDF file
OKOlivier Koole
Olivier Koole
STSharon Tsui
Sharon Tsui
FWFred Wabwire‐Mangen
Fred Wabwire‐Mangen
GKGideon Kwesigabo
Gideon Kwesigabo
JMJoris Menten
Joris Menten
JDJulie Denison
Julie Denison
Objectives: We assessed retention and predictors of attrition (recorded death or loss to follow‐up) in antiretroviral treatment (ART) clinics in Tanzania, Uganda and Zambia.Methods: We conducted a retrospective cohort study among adults (≥18 years) starting ART during 2003–2010. We purposefully selected six health facilities per country and randomly selected 250 patients from each facility. Patients who visited clinics at least once during the 90 days before data abstraction were defined as retained. Data on individual and programme level risk factors for attrition were obtained through chart review and clinic manager interviews. Kaplan–Meier curves for retention across sites were created. Predictors of attrition were assessed using a multivariable Cox‐proportional hazards model, adjusted for site‐level clustering.Results: From 17 facilities, 4147 patients were included. Retention ranged from 52.0% to 96.2% at 1 year to 25.8%–90.4% at 4 years. Multivariable analysis of ART initiation characteristics found the following independent risk factors for attrition: younger age [adjusted hazard ratio (aHR) and 95% confidence interval (95%CI) = 1.30 (1.14–1.47)], WHO stage 4 ([aHR (95% CI): 1.56 (1.29–1.88)], >10% bodyweight loss [aHR (95%CI) = 1.17 (1.00–1.38)], poor functional status [ambulatory aHR (95%CI) = 1.29 (1.09–1.54); bedridden aHR1.54 (1.15–2.07)], and increasing years of clinic operation prior to ART initiation in government facilities [aHR (95%CI) = 1.17 (1.10–1.23)]. Patients with higher CD4 cell count were less likely to experience attrition [aHR (95%CI) = 0.88 (0.78–1.00)] for every log (tenfold) increase. Sites offering community ART dispensing [aHR (95%CI) = 0.55 (0.30–1.01) for women; 0.40 (0.21–0.75) for men] had significantly less attrition.Conclusions: Patient retention to an individual programme worsened over time especially among males, younger persons and those with poor clinical indicators. Community ART drug dispensing programmes could improve retention.

28 January 2015 in AIDS
Verified
Journal Article
Closed access
JDJulie A. Denison
Julie A. Denison
OKOlivier Koole
Olivier Koole
STSharon Tsui
Sharon Tsui
JMJoris Menten
Joris Menten
KTKwasi Torpey
Kwasi Torpey
DBDavid R. Bangsberg
David R. Bangsberg
Objectives: To characterize antiretroviral therapy (ART) adherence across different programmes and examine the relationship between individual and programme characteristics and incomplete adherence among ART clients in sub-Saharan Africa. Design: A cross-sectional study. Methods: Systematically selected ART clients (≥18 years; on ART ≥6 months) attending 18 facilities in three countries (250 clients/facility) were interviewed. Client self-reports (3-day, 30-day, Case Index ≥48 consecutive hours of missed ART), healthcare provider estimates and the pharmacy medication possession ratio (MPR) were used to estimate ART adherence. Participants from two facilities per country underwent HIV RNA testing. Optimal adherence measures were selected on the basis of degree of association with concurrent HIV RNA dichotomized at less than or greater/equal to 1000 copies/ml. Multivariate regression analysis, adjusted for site-level clustering, assessed associations between incomplete adherence and individual and programme factors. Results: A total of 4489 participants were included, of whom 1498 underwent HIV RNA testing. Nonadherence ranged from 3.2% missing at least 48 consecutive hours to 40.1% having an MPR of less than 90%. The percentage with HIV RNA at least 1000 copies/ml ranged from 7.2 to 17.2% across study sites (mean = 9.9%). Having at least 48 consecutive hours of missed ART was the adherence measure most strongly related to virologic failure. Factors significantly related to incomplete adherence included visiting a traditional healer, screening positive for alcohol abuse, experiencing more HIV symptoms, having an ART regimen without nevirapine and greater levels of internalized stigma. Conclusion: Results support more in-depth investigations of the role of traditional healers, and the development of interventions to address alcohol abuse and internalized stigma among treatment-experienced adult ART patients.

12 January 2018 in MMWR. Morbidity and Mortality Weekly Report
Verified
Journal Article
Open access
KBKristin Brown
Kristin Brown
DWDaniel B Williams
Daniel B Williams
SKSteve Kinchen
Steve Kinchen
SSSuzue Saito
Suzue Saito
ERElizabeth Radin
Elizabeth Radin
AVAndrew C Voetsch
Andrew C Voetsch
Report examines prevalence of HIV infection among adolescent girls and young women in seven African countries.

27 November 2015 in MMWR. Morbidity and Mortality Weekly Report
Verified
Journal Article
Open access
AAAndrew F. Auld
Andrew F. Auld
RSRay W. Shiraishi
Ray W. Shiraishi
FMFrancisco Mbofana
Francisco Mbofana
ACAleny Couto
Aleny Couto
EFErnest Benny Fetogang
Ernest Benny Fetogang
TETedd V. Ellerbrock
Tedd V. Ellerbrock
Equitable access to antiretroviral therapy (ART) for men and women with human immunodeficiency virus (HIV) infection is a principle endorsed by most countries and funding bodies, including the U.S. President's Emergency Plan for AIDS (acquired immunodeficiency syndrome) Relief (PEPFAR) (1). To evaluate gender equity in ART access among adults (defined for this report as persons aged ≥15 years), 765,087 adult ART patient medical records from 12 countries in five geographic regions* were analyzed to estimate the ratio of women to men among new ART enrollees for each calendar year during 2002-2013. This annual ratio was compared with estimates from the Joint United Nations Programme on HIV/AIDS (UNAIDS)(†) of the ratio of HIV-infected adult women to men in the general population. In all 10 African countries and Haiti, the most recent estimates of the ratio of adult women to men among new ART enrollees significantly exceeded the UNAIDS estimates for the female-to-male ratio among HIV-infected adults by 23%-83%. In six African countries and Haiti, the ratio of women to men among new adult ART enrollees increased more sharply over time than the estimated UNAIDS female-to-male ratio among adults with HIV in the general population. Increased ART coverage among men is needed to decrease their morbidity and mortality and to reduce HIV incidence among their sexual partners. Reaching more men with HIV testing and linkage-to-care services and adoption of test-and-treat ART eligibility guidelines (i.e., regular testing of adults, and offering treatment to all infected persons with ART, regardless of CD4 cell test results) could reduce gender inequity in ART coverage.